Patients with relapsed or refractory multiple myeloma who receive a combination of Kyprolis (carfilzomib) and dexamethasone have significantly better survival rates than those receiving Velcade (bortezomib) plus…
News
A rabbit virus slowed the growth of multiple myeloma in mice, and eradicated the cancer in a fourth of the animals, a study reported. But…
Patients undergoing hematopoietic (donor) stem cell transplants could benefit from treatment with the experimental drug letermovir, which prevents the common viral infection cytomegalovirus (CMV). These results…
One kind of immune cell helps another stay active for years against invaders, a finding that could lead to therapies for autoimmune diseases and certain…
The U.S. Food and Drug Administration has approved the anti-CD20 therapy Revlimid (lenalidomide) as a maintenance therapy for multiple myeloma patients who received an…
Multiple myeloma (MM) patients treated at facilities that handle more patients may have better survival rates than those treated at lower-volume facilities, according to recent…
MYELOMA
First Myeloma Patient Joins Trial of Therapy for Cancers That Failed to Respond to Treatment
The first multiple myeloma patient has enrolled in a trial of Celyad‘s T-cell therapy for seven types of cancer that have failed to respond to treatment.
A man who calls himself a Hollyweed artist has started an Indiegogo crowdfunding campaign to create T-shirts marking California’s legalization of recreational marijuana — and…
Patients with smoldering multiple myeloma (SMM), an asymptomatic form of myeloma, do not benefit from treatment with the anti-ICAM1 antibody BI-505, according to the results…
A Phase 1 trial will soon be assessing Actimab-M, an anti-CD33 antibody bound to a radioactive compound, in heavily treated multiple myeloma patients, the compound’s developer,…
Recent Posts
- ‘Unprecedented’ response seen with narmafotinib in pancreatic cancer trial
- As a cancer caregiver, I am the ‘lightning rod’ that absorbs the storm
- Myosin wins $2M grant to advance brain cancer treatment MT-125
- Overt forms advisory board to guide ovarian cancer therapy push
- CAR T-cell therapy moving to frontline as myeloma treatment
